These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8571743)

  • 21. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
    Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
    Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
    Cáp J; Babusíková O; Kaiserová E; Jamárik M
    Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease.
    Babusíková O; Glasová M; Kusenda J; Koníková E; Mésárosová A
    Neoplasma; 1994; 41(6):305-13. PubMed ID: 7870213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry.
    Rezaei A; Adib M; Mokarian F; Tebianian M; Nassiri R
    Med Sci Monit; 2003 Aug; 9(8):CR359-62. PubMed ID: 12942032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia.
    Levett D; Middleton P; Cole M; Reid MM
    Med Pediatr Oncol; 2001 Mar; 36(3):365-71. PubMed ID: 11241438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].
    Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
    Chen JS; Hsiao CC; Sheen JM; Cheng CN
    Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Detection of minimal residual disease in acute leukemias by flow cytometry].
    Scolnik MP
    Medicina (B Aires); 2000; 60 Suppl 2():83-6. PubMed ID: 11188938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
    Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Detection of minimal residual disease in childhood hematological malignancies and its clinical significance].
    Tang S; Lu S; Zhang X; Ran C; Huang D; Wei X
    Zhonghua Xue Ye Xue Za Zhi; 2000 Jan; 21(1):27-9. PubMed ID: 11876957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
    Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
    Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
    Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Residual disease: the hematologist's point of view].
    Quesnel B; Preudhomme C
    Bull Cancer; 2001 Jun; 88(6):571-5. PubMed ID: 11459703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
    Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
    Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.